Provider review
DirectMeds Review: "Clinically Proven" Sermorelin Has No Clinical Trial
DirectMeds sells sermorelin at $199 a month under a heading that reads "Clinically Proven Peptide Therapy". There is no clinical trial. A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention under any of six query forms, and PubMed holds no randomised-trial publication for it — findings established with controls that returned 158, 17 and 10 records for molecules that do have trials. This matters more here than it would elsewhere, because DirectMeds is under an open FDA warning letter, issued September 2025 and still without a close-out, for implying its compounded products carry an approved product's standing. Eleven months on, its tirzepatide page still lists "FDA approved for long term weight loss" among the product's features — on a page that says "compounded" six times and "not FDA-approved" once. The same page calls tirzepatide a "GLP-1 receptor antagonist", which is the opposite of what it is.
Compounded only
Phase 3 trials
Named
September 2025
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens directmeds.com. A link is not a recommendation to take anything.
Provenance
What DirectMeds actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin ("Sermorix") — $199 a month, printed as "$6.42 per day", which is $199 over 31 days and is arithmetically correct. Billing runs every 30 days under the Terms, so a year is about 12.17 charges rather than 12.
- NAD+ injection (500 mg / 1000 mg) — $199 a month, printed as "$6.42 per day". Offered at 500 mg and 1000 mg for the same headline price.
- Semaglutide injection (compounded) — $297 a month, printed as "$9.58 per day" — correct arithmetic over 31 days. ⚠ A "$249/month for sublingual Semaglutide" figure appears in FAQ boilerplate repeated on every product page; no sublingual product page exists, so it is not filed as a price.
- Tirzepatide injection (compounded) — $399 a month — printed with "$9.58 per day" beneath it. $399 over 31 days is $12.87. $9.58 is the per-day figure for the $297 semaglutide product, copied onto this page, understating the daily cost by about a quarter.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Products with a human trial
Out of 4 reviewed here.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from DirectMeds’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Sermorelin ("Sermorix")Sermorelin · Compounded (503A)No trial supports this claim
“Sermorelin is a peptide that stimulates your body's natural production of growth hormone, supporting improved sleep, recovery, energy, and body composition over time — all without introducing synthetic hormones. […] Clinically Proven Peptide Therapy. Sermorix contains Sermorelin, a bioidentical peptide that stimulates your body's natural production of growth hormone… making it a safer and more sustainable option. […] One of the first benefits users notice is deeper, more restful sleep. Sermorix helps regulate circadian rhythms.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies the intervention search returns are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified "GHRH" used as a diagnostic stimulation agent. In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomised-controlled-trial or clinical-trial publication type; the one record pairing it with ageing or body composition is a narrative review (PMID 32257855). The searches discriminate: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
"Clinically Proven Peptide Therapy" is a heading on this page, and it is false in the plainest sense available to this site: there is no clinical trial of sermorelin to be proven by. Not a weak trial, not an unblinded one — no registered interventional record naming the molecule, and no randomised-trial publication. Everything below the heading inherits the problem. "One of the first benefits users notice is deeper, more restful sleep" is a claim about incidence and ordering; "helps regulate circadian rhythms" is a mechanism nothing on the site measures; "a safer and more sustainable option" than synthetic HGH is a comparative safety claim from a company that has run no comparison. The one defensible sentence is that sermorelin stimulates the body's own growth hormone rather than supplying it — that much is real pharmacology.1,2
NAD+ injection (500 mg / 1000 mg)NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Power up your cells with injectable NAD+ — the ultimate biohack for energy, focus, and longevity. This fast-acting formula fuels your metabolism, sharpens your mind, and helps you feel younger from the inside out. […] Sharpen Your Mind: Enhance cognitive function, focus, and memory for optimal mental clarity and performance. Defend Against Aging: Protect your cells from damage, boost your immune system, and promote healthy aging. Elevate Your Athletic Performance: Optimize muscle recovery, reduce inflammation, and push your physical limits.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomised-controlled-trial publication type, returns zero records. No registered trial of injected NAD+ reports a cognitive, immune, athletic-performance or inflammatory endpoint. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
This is the least hedged product page in the entire wave. Nine distinct outcomes are asserted as things the injection does — energy, metabolism, focus, memory, cognitive function, immune function, muscle recovery, reduced inflammation, feeling younger — with no "may" in front of most of them and no citation behind any. Injected NAD+ has no completed randomised trial of any kind, and no registered study reports a cognitive, immune, athletic or inflammatory endpoint for it. "Boost your immune system" and "reduce inflammation" are the two that should not appear on a prescription product page without evidence. Calling it "the ultimate biohack" is the register of a supplement advertisement, on a compounded drug requiring a prescription.3
Semaglutide injection (compounded)Semaglutide · Compounded (503A)Claim matches the trials
“Convenient GLP-1–based program with once-weekly dosing when prescribed. […] May support healthy weight management when combined with lifestyle changes. Can help promote balanced appetite and fullness cues. May assist with healthy metabolic function. […] Semaglutide works with your body's natural signals to help reduce hunger.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product. No compounded semaglutide from any seller has been through a registered trial.
Notably, and to DirectMeds' credit, this is the page that reads as though a lawyer went through it after the FDA letter. Every benefit is hedged — "may support", "can help promote", "may assist" — no trial is named, no percentage is quoted, and the appetite and metabolic effects described are genuinely established for the molecule at phase 3. The standing caveat applies: STEP 1 tested the approved finished product, not a compounded preparation, and the page does not draw that line. Set against the tirzepatide page next to it, the contrast is stark enough to suggest only one of the two was revised.4
Tirzepatide injection (compounded)Tirzepatide · Compounded (503A)No trial supports this claim
“Convenient GLP-1–based program with once-weekly dosing when prescribed. Features: Once weekly injection… Easy-to-use, prefilled pen device. Lose more weight compared to diet and exercise alone. Reduce glucagon release. FDA approved for long term weight loss. High bioavailability (89%). […] Long acting GLP-1 receptor antagonist.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product — Zepbound — at the highest tolerated dose over 72 weeks. It is that approval, not DirectMeds', that the page's "FDA approved" claim borrows.
Four errors in one Features list, and the first is the one FDA wrote to this company about. "FDA approved for long term weight loss" appears on a page that says "compounded" six times and "not FDA-approved" once: the compounded preparation DirectMeds dispenses holds no approval, and the approval being invoked belongs to Zepbound. That is the same claim class cited in warning letter 716822, still live eleven months after it was issued. "Long acting GLP-1 receptor ANTAGONIST" is the opposite of the drug's action — tirzepatide is an agonist, and a dual GIP/GLP-1 agonist at that; the word "agonist" appears nowhere on the page, and the GIP half is never mentioned. "Easy-to-use, prefilled pen device" describes the brand presentation, not a compounded vial. And "High bioavailability (89%)" is offered with no source. All four strings were verified in the raw HTML and all four occur on this page and zero times on the semaglutide page beside it.5
Dispensing chain
Who actually fills your prescription
- CraftedRx (Warrenton, MO)
- ChemistryRx (Folcroft, PA)
Read the full account
DirectMeds names its dispensing pharmacies in full — with street addresses, phone numbers and a state-by-state map — which puts it among the best supply-chain disclosures in this roster: "Valid prescriptions for individuals residing in [43 jurisdictions] will be filled by: CraftedRx, 609 N State Hwy 47, Suite C, Warrenton, MO 63383, +1 (888) 788-0485. Valid prescriptions for individuals residing in Alabama, California, Connecticut, North Carolina, South Carolina, and Washington will be filled by: ChemistryRx, 950 Henderson Blvd, Folcroft, PA 19032, +1 (877) 989-6128." ⚠⚠ THREE THINGS QUALIFY THAT, AND THEY MATTER FOR A PEPTIDE BUYER. First, the disclosure lives on the `/portal/products/` commerce pages, not on the marketing site — a reader browsing the ordinary product pages never sees it, and a blog post actually titled "Meet the Pharmacy" names nobody, describing only "pharmacies that share our values of safety, purity, and excellence" and promising a video tour that is not embedded on the page. Second, and decisively for this site: the naming covers the GLP-1 line ONLY. The portal pages for sermorelin and NAD+ name no pharmacy and state no regulatory category — zero occurrences of either pharmacy name on either page. So the products FDA wrote to DirectMeds about are disclosed, and the two peptides this review covers are not. Third, the category claimed is not supported: the portal states "Our pharmacies are 503B compounding pharmacies" and that "Our pharmacy is a sterile facility approved to create specific GLP-1 medications". Neither CraftedRx nor ChemistryRx appears on FDA's registered outsourcing-facility list, read 2026-08-10 across all 99 rows with Empower and Olympia as positive controls that both returned present. ⛔ That absence does not imply either pharmacy is unlicensed — a 503A pharmacy is entirely lawful and is the norm for patient-specific compounding. What it means is that the 503B designation is not evidenced, and that FDA approves no compounder and no compounded product, so "approved to create specific GLP-1 medications" cannot be right in any reading.
Read on August 2026 from https://directmeds.com/portal/products/semaglutide-injection
Quality
Third-party testing, and what is published
Yes
Describes a testing regime
A described programme, not a document.
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
DirectMeds asserts testing and publishes no result. The claim recurs across the product pages in identical wording: "Our medications undergo third-party testing for purity, safety, and potency." No certificate of analysis, lot number, laboratory name, batch record, potency figure or sterility result appears anywhere on the site, for any product. `publishesTesting` is true and `coaPublic` false precisely to hold those two apart: the company describes a testing regime, and a prospective customer cannot read a single output of it. ⚠ The supporting claim about the facilities does not hold up either. The portal says "Our pharmacies are 503B compounding pharmacies… a sterile facility approved to create specific GLP-1 medications", but neither named pharmacy is on FDA's registered outsourcing-facility list (99 rows, read 2026-08-10, with two positive controls present). ⚠ The trust signals on the same pages do not agree with each other: every product page carries both "250,000+ happy customers" in its header and "53,000 satisfied patients and an average 4.8-star rating" in its body, alongside a "4.6" rating in the header — two customer counts differing roughly fivefold and two star ratings, on one page.
Read on August 2026 from https://directmeds.com/products/sermorelin
Licensing
Licensed to dispense, and where
Coverage
All states except Mississippi and Louisiana, plus Washington, D.C.
Read the full licensing claim
DirectMeds publishes its coverage as data rather than as a slogan, and it is one of the clearest state disclosures in this roster: a pharmacy-by-state map assigning 43 jurisdictions including Washington D.C. to CraftedRx and six states — Alabama, California, Connecticut, North Carolina, South Carolina and Washington — to ChemistryRx, with an explicit exclusion: "Direct Meds does not provide services to individuals residing in Mississippi & Louisiana, where prescription of weight loss medications via telehealth is prohibited." A named exclusion with a stated reason is rare here. ⚠ Note that this map is published on the GLP-1 portal pages; no state coverage is published for sermorelin or NAD+ specifically, so a peptide buyer cannot confirm the same map governs them. Prescriptions are described as "reviewed by a real provider before being shipped"; no individual clinician is named anywhere and no licence number is published. ⚠ Two addresses of record exist for the company — a Texas PMB in the site footer and a Utah address in the FDA warning letter — and its Terms are governed by Utah law.
Named as outside that footprint
Read on August 2026 from https://directmeds.com/portal/products/semaglutide-injection
Regulatory
The FDA warning letter
Issued September 2025
directmeds.com, Inc. dba DirectMeds — 716822. Concerns marketing and labelling.
Read the full allegation
FDA reviewed directmeds.com in August 2025 and quoted three passages from the site, including "Compounded semaglutide contains the same active ingredient as branded semaglutide" and, on tirzepatide, "Compounded formulations use the same active ingredient as the brand-name drug, customized by licensed compounding pharmacies to meet your needs." FDA's objection: "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not." That makes the products misbranded under FD&C Act 502(a) and 502(bb). The letter is confined to advertising language — it alleges nothing about sterility, potency, contamination, or the pharmacies that fill the prescriptions. FDA notes the cited claims "do not represent an exhaustive list".
What has changed since
Checked 10 August 2026, eleven months on, and the answer is mixed. The three specific sentences FDA quoted have been removed. The semaglutide page has been rewritten into consistent hedged language — "may support", "can help promote" — and reads as though it was revised in response. ⚠ The tirzepatide page has not: its Features list still states "FDA approved for long term weight loss", on a page that elsewhere says "compounded" six times and "not FDA-approved" once. FDA's own letter warned that the quoted claims "do not represent an exhaustive list", and this is the kind of claim it was describing. No close-out notice has been issued, so the letter remains open; the control used to confirm the close-out column reads correctly is Belmar's letter of 31 March 2023, closed out 30 October 2023.
Assessment
What holds up, and what does not
- It names its dispensing pharmacies in full — CraftedRx in Warrenton, Missouri and ChemistryRx in Folcroft, Pennsylvania — with street addresses, phone numbers and a state-by-state map. Very little else in this category does.
- It publishes an explicit state exclusion with a reason: no service in Mississippi or Louisiana, "where prescription of weight loss medications via telehealth is prohibited".
- Its semaglutide page reads as genuinely revised after the FDA letter: consistent "may support" and "can help promote" hedging, no trial named, no percentage claimed.
Show 4 more
- Shipping and handling are described concretely — same-day dispatch before 2pm Central, next-day UPS in a temperature-controlled package, tracking on every shipment, and shipments insured against loss.
- The dosing explanation is honest about titration: start low, increase every four weeks, with the schedule set by the prescriber rather than the storefront.
- The per-day arithmetic is right on three of the four products, and the price shown is inclusive of provider and shipping rather than a medication-only figure.
- Prescriptions are reviewed by a provider before shipping, and multiple supply lengths (30, 90, 180 and 360 days) are offered rather than a single locked plan.
- Sermorelin is sold under the heading "Clinically Proven Peptide Therapy". No registry holds an interventional record naming sermorelin, and PubMed holds no randomised-trial publication for it.
- The tirzepatide page lists "FDA approved for long term weight loss" as a product feature, on a page that says "compounded" six times and "not FDA-approved" once. That is the claim class FDA cited the company for.
- The same page calls tirzepatide a "Long acting GLP-1 receptor antagonist". It is an agonist, and a dual GIP/GLP-1 agonist — the word "agonist" appears nowhere on the page and GIP is never mentioned.
Show 11 more
- It describes an "Easy-to-use, prefilled pen device" — the brand presentation — for a compounded product, and cites "High bioavailability (89%)" with no source.
- The tirzepatide page prints "$399 /month" with "$9.58 per day" beneath it. $399 over 31 days is $12.87; $9.58 is the semaglutide page's figure, understating the daily cost by about a quarter.
- FDA warning letter 716822 is open — issued 9 September 2025 with no close-out eleven months later. It concerns advertising language, not product quality, and is disclosed here rather than treated as disqualifying.
- The NAD+ page asserts nine outcomes including "boost your immune system" and "reduce inflammation", unhedged and uncited, for an injection with no completed human trial. It calls it "the ultimate biohack".
- Neither peptide page names a pharmacy or states a regulatory category — the disclosure that exists covers only the GLP-1 line.
- "Our pharmacies are 503B compounding pharmacies" is not supported: neither named pharmacy appears on FDA's registered outsourcing-facility list, checked with working positive controls.
- "Our pharmacy is a sterile facility approved to create specific GLP-1 medications" — FDA approves no compounder and no compounded product.
- A blog post titled "Meet the Pharmacy" names no pharmacy and promises a video tour that is not embedded on the page.
- "Our medications undergo third-party testing for purity, safety, and potency" is repeated across the site with no lot number, laboratory, date or document ever published.
- Every product page carries two different customer counts — "250,000+ happy customers" and "53,000 satisfied patients" — and two different ratings, 4.6 and 4.8.
- A "$249/month sublingual Semaglutide" price is repeated in FAQ boilerplate on every product page, and no sublingual product page exists.
Verdict
The bottom line
DirectMeds does the hardest disclosure in this category better than almost anyone and the easiest one worse than almost anyone. It names both of its pharmacies with street addresses, phone numbers and a state-by-state map, and it names the two states it will not serve and why. Then it sells sermorelin under a heading reading "Clinically Proven Peptide Therapy" for a molecule with no clinical trial in existence, sells NAD+ as "the ultimate biohack" that will boost your immune system, and — eleven months into an open FDA warning letter about implying its compounded products carry an approved drug's standing — still lists "FDA approved for long term weight loss" as a feature of its compounded tirzepatide, on a page that calls the drug an antagonist when it is an agonist. The semaglutide page shows the company can write carefully when it decides to. The tirzepatide and peptide pages show what happens where it has not. If you buy here, you will at least know which pharmacy fills your prescription — provided you are buying a GLP-1, because for the peptides that disclosure does not exist.
Opens directmeds.com. A link is not a recommendation to take anything.
"Clinically Proven Peptide Therapy"
That is a heading on DirectMeds' sermorelin page, above a $199-a-month product it brands Sermorix.
Here is what the registries hold for the molecule underneath it.
A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention — none, at any phase, at any status. 1 Six query forms were run: "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", and "Geref", the brand name under which sermorelin was once approved in the United States and has since been withdrawn. A free-text pass across every field of every record was run as well.
The search does return 27 studies, and every one of them is a different molecule — tesamorelin (marketed as Egrifta), GHRH(1-44), or an unspecified "GHRH" used as a diagnostic agent for pituitary stimulation testing. None is sermorelin.
PubMed holds 24 records mentioning sermorelin in a title or abstract, and zero carry the randomised-controlled-trial or clinical-trial publication type. 2 The single paper pairing sermorelin with ageing or body composition is a narrative review in Translational Andrology and Urology.
A result like that is usually a broken query, so the same searches were run against three molecules that should be there. Tirzepatide: 158 registry records naming it, 126 trial papers. Tesamorelin: 17 and 21. Bremelanotide: 10 and 11. The instrument works.
So "clinically proven" is not an overstatement of a weak result. There is no result. There is no trial to have proven anything.
Everything under the heading inherits that. "One of the first benefits users notice is deeper, more restful sleep" is a claim about which effects arrive first — the shape of a trial finding. "Sermorix helps regulate circadian rhythms" is a mechanism nothing on the site measures. "A safer and more sustainable option" than synthetic HGH is a comparative safety claim, and no one has run the comparison.
One sentence on the page is fair: sermorelin stimulates the body's own growth hormone rather than supplying it. That much is real pharmacology, and it is the honest core the rest is built on top of.
Full analysis — 5 more sectionsThe letter, and the page that did not get the memo · The pharmacy DirectMeds does name — and the one it does not · The NAD+ page · Numbers that do not agree · What this means if you are buying
The letter, and the page that did not get the memo
On 9 September 2025 FDA issued warning letter 716822 to directmeds.com, Inc. dba DirectMeds. 6 It quoted three passages from the site, including "Compounded semaglutide contains the same active ingredient as branded semaglutide", and stated the objection plainly:
"Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not."
That is a labelling and advertising finding under FD&C Act 502(a) and 502(bb). It alleges nothing about sterility, potency, contamination or the pharmacies, and this review does not treat it as though it did.
The three quoted sentences are gone. The semaglutide page has plainly been rewritten — every benefit now reads "may support healthy weight management", "can help promote balanced appetite and fullness cues", "may assist with healthy metabolic function". No trial is named, no percentage is quoted. It is a careful page.
Now open the tirzepatide page next to it. Its Features list, verbatim:
"Once weekly injection… Easy-to-use, prefilled pen device. Lose more weight compared to diet and exercise alone. Reduce glucagon release. FDA approved for long term weight loss. High bioavailability (89%)."
And below: "Long acting GLP-1 receptor antagonist."
Four things are wrong there.
"FDA approved for long term weight loss." DirectMeds sells compounded tirzepatide. Compounded preparations hold no FDA approval — and the same page says "compounded" six times and "not FDA-approved" once. The approval being borrowed belongs to Zepbound. This is the exact claim class the warning letter was about, still live eleven months later, and FDA's letter had explicitly warned that its quoted examples "do not represent an exhaustive list".
"GLP-1 receptor antagonist." An antagonist blocks a receptor. Tirzepatide activates it — it is an agonist, and specifically a dual GIP/GLP-1 agonist, which is what distinguishes it from semaglutide. The word "agonist" appears nowhere on the page, and GIP is never mentioned at all.
"Prefilled pen device." That is the branded presentation. Compounded tirzepatide is dispensed in vials.
"High bioavailability (89%)." Offered with no source, on a page that cites nothing.
All four strings were checked in the served HTML. All four appear on the tirzepatide page and none appears on the semaglutide page beside it. One of the two pages was revised after the letter.
The pharmacy DirectMeds does name — and the one it does not
This is where DirectMeds is genuinely better than most of its competitors, and where the story turns.
Its portal pages publish the dispensing chain properly:
"Valid prescriptions for individuals residing in [43 jurisdictions] will be filled by: CraftedRx, 609 N State Hwy 47, Suite C, Warrenton, MO 63383, +1 (888) 788-0485.
>
Valid prescriptions for individuals residing in Alabama, California, Connecticut, North Carolina, South Carolina, and Washington will be filled by: ChemistryRx, 950 Henderson Blvd, Folcroft, PA 19032, +1 (877) 989-6128."
Street addresses. Phone numbers. A state-by-state map. Plus a named exclusion with a reason — no service in Mississippi or Louisiana, "where prescription of weight loss medications via telehealth is prohibited". Very little in this category comes close.
Three things qualify it.
It is not where you would look. That map is on `/portal/products/`, the commerce layer. A reader browsing the ordinary marketing pages never encounters it. And DirectMeds publishes a blog post actually titled "Meet the Pharmacy" which names no pharmacy at all — it offers only "pharmacies that share our values of safety, purity, and excellence" and promises that "in our latest video, Meet the Pharmacy, you'll get an exclusive behind-the-scenes tour". There is no video on the page: no iframe, no player, nothing but the site footer's YouTube icon.
It does not cover the peptides. The pharmacy map appears on the semaglutide and tirzepatide portal pages. The portal pages for sermorelin and NAD+ name no pharmacy and state no regulatory category — zero occurrences of either pharmacy name on either page. So the products FDA wrote to DirectMeds about are disclosed, and the two products this site reviews are not.
The category claimed is not evidenced. The portal says: "Our pharmacies are 503B compounding pharmacies… Our pharmacy is a sterile facility approved to create specific GLP-1 medications."
FDA publishes a register of outsourcing facilities — the 503B list. It was read on 10 August 2026, all 99 rows. Neither CraftedRx nor ChemistryRx is on it, and "Warrenton" returns nothing. The list reads correctly: Empower and Olympia, both well-known outsourcing facilities, are present as controls.
Two cautions on what that does and does not mean. It does not mean either pharmacy is unlicensed or improper — a 503A pharmacy compounding for named patients is entirely lawful and is the norm for exactly this kind of product. What it means is that the 503B designation DirectMeds claims is not supported by FDA's own register. And "approved" is wrong under any reading: FDA approves no compounder and no compounded product, which is the substance of the letter DirectMeds is already under.
(A different company at the same Folcroft, Pennsylvania address city does appear on the register. A shared city is not a match, and this review files nothing on the resemblance.)
The NAD+ page
$199 a month. The copy:
"Power up your cells with injectable NAD+ — the ultimate biohack for energy, focus, and longevity… Sharpen Your Mind: Enhance cognitive function, focus, and memory… Defend Against Aging: Protect your cells from damage, boost your immune system… Elevate Your Athletic Performance: Optimize muscle recovery, reduce inflammation, and push your physical limits."
Nine outcomes, most without a "may" in front of them, none with a citation.
Injected NAD+ has no completed randomised trial supporting a restoration-of-function claim, and no registered study of it reports a cognitive, immune, athletic-performance or inflammatory endpoint. 3 The substantial human literature is about oral precursors — nicotinamide riboside and nicotinamide mononucleotide — different molecules taken a different way.
"Boost your immune system" and "reduce inflammation" are the two that should not sit unhedged on a prescription drug page. "The ultimate biohack" is the register of a supplement advertisement.
Numbers that do not agree
Small things, but they are on every page.
Each product page shows "250,000+ happy customers" in its header and "53,000 satisfied patients and an average 4.8-star rating" in its body — beside a "4.6" in the header. Two customer counts differing roughly fivefold and two star ratings, on one page.
The FAQ block repeated on every product page says "Plans start at $249/month for sublingual Semaglutide". There is no sublingual semaglutide product page. That price is not filed here, because a price with no product is not a price.
And the tirzepatide page prints "$399 /month" with "$9.58 per day" beneath it. $399 over 31 days is $12.87. $9.58 a day is $297 — the semaglutide page's figure, copied across, understating the daily cost by about a quarter.
What this means if you are buying
For semaglutide, this is a reasonable place to look. The page is honest, the price includes the provider and shipping, the pharmacy is named with an address you can ring, and the state map tells you which one you get.
For tirzepatide, the same pharmacy disclosure applies, but do not take the product page's word for anything: it is not FDA approved, it is not an antagonist, it does not come in a prefilled pen, and it costs $12.87 a day, not $9.58.
For sermorelin, "clinically proven" describes a body of evidence that does not exist. You would also be buying a peptide whose dispensing pharmacy DirectMeds does not name, on a page that states no regulatory category — the disclosure that makes this company unusual stops before it reaches the product you are looking at.
For NAD+, the same gap in disclosure, and the least hedged page in this entire review wave.
Questions
Frequently asked questions
Is DirectMeds' sermorelin really "clinically proven"?
No. The heading appears on its product page; the trial does not exist. A ClinicalTrials.gov search on 10 August 2026 returned no interventional record naming sermorelin as the intervention, across six query forms — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and its withdrawn brand name "Geref" — plus a free-text search of every field. The 27 studies returned are all different molecules, mostly tesamorelin and GHRH(1-44). PubMed holds 24 records mentioning sermorelin and none with the randomised-controlled-trial or clinical-trial publication type. The searches were controlled: in the same pass tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11. So this is a result rather than a failed query. It says nothing about whether sermorelin is safe; it says no registered trial has measured whether it does what the page sells it for.
Does the FDA warning letter mean DirectMeds' products are unsafe?
The letter does not say that and neither does this review. Warning letter 716822, issued 9 September 2025, cites DirectMeds under FD&C Act 502(a) and 502(bb) for advertising language — specifically for claims implying its compounded products are the same as FDA-approved ones. FDA's words: "Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not." There is no allegation anywhere in it about sterility, potency, contamination or the pharmacies. What is notable is what has happened since: the three sentences FDA quoted are gone and the semaglutide page has been carefully rewritten, but the tirzepatide page still lists "FDA approved for long term weight loss" as a product feature — and FDA's letter warned that its examples "do not represent an exhaustive list". No close-out has been issued, so the letter remains open.
Which pharmacy fills a DirectMeds prescription?
For GLP-1s, DirectMeds tells you exactly — and this is the best thing about the company. Its portal publishes a state-by-state map: CraftedRx, 609 N State Hwy 47 Suite C, Warrenton, MO 63383, (888) 788-0485 for 43 jurisdictions including Washington D.C.; and ChemistryRx, 950 Henderson Blvd, Folcroft, PA 19032, (877) 989-6128 for Alabama, California, Connecticut, North Carolina, South Carolina and Washington. Street addresses and phone numbers, which almost nothing else in this category publishes. Two caveats. The map is on the /portal/products/ commerce pages, not the marketing site, and a blog post titled "Meet the Pharmacy" names nobody and promises a video that is not embedded. And for sermorelin and NAD+ — the two products this site reviews — no pharmacy is named at all.
Are DirectMeds' pharmacies really 503B facilities?
Not according to FDA's own register. The portal states "Our pharmacies are 503B compounding pharmacies" and that "Our pharmacy is a sterile facility approved to create specific GLP-1 medications". FDA publishes a list of registered outsourcing facilities — the 503B register — and it was read in full on 10 August 2026, all 99 rows. Neither CraftedRx nor ChemistryRx appears on it. The list reads correctly: Empower and Olympia, both established outsourcing facilities, were present in the same pass as controls. Two things this does not mean: it does not mean either pharmacy is unlicensed or improper, because a 503A pharmacy compounding for a named patient is lawful and ordinary; and it is not a finding about product quality. What it means is that the 503B designation is unevidenced, and that "approved" is wrong in any case — FDA approves no compounder and no compounded product.
What does DirectMeds cost?
$199 a month for sermorelin, $199 for NAD+, $297 for compounded semaglutide and $399 for compounded tirzepatide, each described as all-inclusive of the medication, provider support and shipping, billed every 30 days. Check the per-day figures, because one is wrong: the tirzepatide page prints "$399 /month" with "$9.58 per day" beneath it, but $399 over 31 days is $12.87 — $9.58 is the semaglutide page's figure copied across, understating the daily cost by about a quarter. The other three are arithmetically correct. Ignore the "$249/month for sublingual Semaglutide" in the FAQ block repeated on every product page: no sublingual product page exists on the site.
Does DirectMeds publish test results?
It claims testing and publishes no result. The sentence "Our medications undergo third-party testing for purity, safety, and potency" is repeated across the product pages. No certificate of analysis, lot number, laboratory name, batch record, potency figure or sterility result appears anywhere on the site, for any product — which is why this review records testing as claimed but no certificate as public. Those are separate questions and collapsing them would let an assertion read like a document. Worth noting alongside: the trust figures on those same pages do not agree with each other, with every product page carrying both "250,000+ happy customers" and "53,000 satisfied patients", and both a 4.6 and a 4.8 star rating.
Glossary
Key terms
Show definitions
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29), which signals the pituitary to release the body's own growth hormone rather than supplying it directly. Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
- Agonist vs antagonist
- An agonist activates a receptor; an antagonist blocks it. They produce opposite effects. Tirzepatide is a dual GIP/GLP-1 agonist. DirectMeds' tirzepatide page calls it a "GLP-1 receptor antagonist".
- 503B outsourcing facility
- A compounder that has registered with FDA under section 503B, submits to inspection and must follow CGMP. Registration is not approval, and FDA publishes the register publicly. Neither pharmacy DirectMeds names appears on it.
- 503A pharmacy
- A state-licensed pharmacy compounding a preparation for an individual named patient against a prescription. This is lawful, ordinary, and what most telehealth peptide products come from — it is simply not the same thing as a 503B facility.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off DirectMeds's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 7 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. The 27 studies returned are tesamorelin, GHRH(1-44) or unspecified diagnostic GHRH. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: "sermorelin"[tiab] returns 24 records; "sermorelin"[tiab] AND randomized controlled trial[pt] returns 0, as does the clinical trial publication type. The single record pairing sermorelin with ageing or body composition is a narrative review, PMID 32257855. Positive controls: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, and no registered study reporting a cognitive, immune, athletic-performance or inflammatory endpoint. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US Food and Drug Administration (2025). Warning Letter 716822 to directmeds.com, Inc. dba DirectMeds, issued 2025-09-09. Cited under FD&C Act 502(a) and 502(bb) for claims implying compounded products are the same as FDA-approved products; no product-quality allegation. No close-out as of 2026-08-10.. FDA warning letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/directmedscom-inc-dba-directmeds-716822-09092025
- US Food and Drug Administration (2026). Registered Outsourcing Facilities (section 503B register) — all 99 rows read 2026-08-10. Neither CraftedRx nor ChemistryRx appears; "Warrenton" returns 0. Positive controls Empower and Olympia both present.. FDA human drug compounding. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.